Literature DB >> 30302225

Early mortality and survival in older adults with acute myeloid leukemia.

Manisha Pant1,1, Vijaya Raj Bhatt2,2.   

Abstract

Entities:  

Keywords:  acute myeloid leukemia; chemotherapy; geriatric assessment; hematopoietic cell transplant; novel therapy; older adult; survival

Year:  2017        PMID： 30302225      PMCID： PMC6171990          DOI： 10.2217/ijh-2017-0013

Source DB:  PubMed          Journal:  Int J Hematol Oncol        ISSN： 2045-1393


× No keyword cloud information.
  21 in total

1.  Survival for older patients with acute myeloid leukemia: a population-based study.

Authors:  Betul Oran; Daniel J Weisdorf
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

2.  Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study.

Authors:  Anjali Shah; Therese M-L Andersson; Bernard Rachet; Magnus Björkholm; Paul C Lambert
Journal:  Br J Haematol       Date:  2013-06-21       Impact factor: 6.998

3.  Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.

Authors:  William Blum; Ramiro Garzon; Rebecca B Klisovic; Sebastian Schwind; Alison Walker; Susan Geyer; Shujun Liu; Violaine Havelange; Heiko Becker; Larry Schaaf; Jon Mickle; Hollie Devine; Cheryl Kefauver; Steven M Devine; Kenneth K Chan; Nyla A Heerema; Clara D Bloomfield; Michael R Grever; John C Byrd; Miguel Villalona-Calero; Carlo M Croce; Guido Marcucci
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

4.  On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.

Authors:  B Löwenberg; R Zittoun; H Kerkhofs; U Jehn; J Abels; L Debusscher; C Cauchie; M Peetermans; G Solbu; S Suciu
Journal:  J Clin Oncol       Date:  1989-09       Impact factor: 44.544

5.  Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.

Authors:  R Coleman Lindsley; Brenton G Mar; Emanuele Mazzola; Peter V Grauman; Sarah Shareef; Steven L Allen; Arnaud Pigneux; Meir Wetzler; Robert K Stuart; Harry P Erba; Lloyd E Damon; Bayard L Powell; Neal Lindeman; David P Steensma; Martha Wadleigh; Daniel J DeAngelo; Donna Neuberg; Richard M Stone; Benjamin L Ebert
Journal:  Blood       Date:  2014-12-30       Impact factor: 22.113

6.  Age and acute myeloid leukemia.

Authors:  Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

7.  High-dose daunorubicin in older patients with acute myeloid leukemia.

Authors:  Bob Löwenberg; Gert J Ossenkoppele; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

8.  Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.

Authors:  Claude Gardin; Sylvie Chevret; Cécile Pautas; Pascal Turlure; Emmanuel Raffoux; Xavier Thomas; Bruno Quesnel; Thierry de Revel; Stéphane de Botton; Nathalie Gachard; Aline Renneville; Nicolas Boissel; Claude Preudhomme; Christine Terré; Pierre Fenaux; Dominique Bordessoule; Karine Celli-Lebras; Sylvie Castaigne; Hervé Dombret
Journal:  J Clin Oncol       Date:  2012-12-17       Impact factor: 44.544

9.  Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML).

Authors:  Bernard Tawfik; Timothy S Pardee; Scott Isom; Sarunas Sliesoraitis; Allison Winter; Julia Lawrence; Bayard L Powell; Heidi D Klepin
Journal:  J Geriatr Oncol       Date:  2015-10-30       Impact factor: 3.599

Review 10.  Emerging therapeutic drugs for AML.

Authors:  Eytan M Stein; Martin S Tallman
Journal:  Blood       Date:  2015-12-10       Impact factor: 22.113
View more
  3 in total

1.  Preferences of adults with cancer for systemic cancer treatment: do preferences differ based on age?

Authors:  Prajwal Dhakal; Christopher S Wichman; Bunny Pozehl; Meaghann Weaver; Alfred L Fisher; Julie Vose; R Gregory Bociek; Vijaya R Bhatt
Journal:  Future Oncol       Date:  2021-11-11       Impact factor: 3.674

Review 2.  Determination of fitness and therapeutic options in older patients with acute myeloid leukemia.

Authors:  Jorge E Cortes; Priyanka Mehta
Journal:  Am J Hematol       Date:  2021-01-12       Impact factor: 10.047

3.  Usefulness of Charlson Comorbidity Index to Predict Early Mortality and Overall Survival in Older Patients With Acute Myeloid Leukemia.

Authors:  Prajwal Dhakal; Valerie Shostrom; Zaid S Al-Kadhimi; Lori J Maness; Krishna Gundabolu; Vijaya Raj Bhatt
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-07-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.